scil

ArtisanArtisan Coral BioNetCoral BioNet

Scil Investment Holding GmbHScil Investment Holding GmbH

Scil Technology Holding GmbHScil Technology Holding GmbH

ScilAnimal Care

ScilAnimal Care

ScilDiagnostics

ScilDiagnostics

ScilPharma-ceuticals

ScilPharma-ceuticals

ScilProtein

ScilProtein

BioNetLaboratories

Asia Diagnostics

BioNetLaboratories

Asia Diagnostics

SCIL Finance Holding GmbH

Stefan Engelhorn

20 % 80 %

scil

Scil Technology Holding

• Use niches in Life Science to develop, manufacture and marketdiagnostics and therapeutics

• Use investment possibilities to synergize the existing operativebusiness

• Bridge the gap between VC funded companies and big pharmaby using professional industrial development know how

• Create profit along the value chain for our partners and ourselves

scil

Scil Technology Holding: Objectives

Short term (3 years):

Focus on industrial development know how and use existing network in diagnostics and therapeutics to acquire projects and to generate short term cash flow

Medium term (3 - 6 years):

Focus on technologies around proteins. Use know how in proteintechnology for own developments and as service. Collaborate withpartners for co-developments and co-marketing

Long term (> 6 years):

Use the synergistic potential of diagnostic and therapeutic activitiesto create integrated solutions for more efficient treatments in nicheindications

scil

Scil Technology Holding: Competencies

An one year old privately own company which is actively involved in the development and marketing of diagnostics and therapeutics

Diagnostics• proprietary immunoassay technology and data transfer concept• innovative reagent packaging concept• sales organizations in Europe, US, Canada and Asia (Singapore)• products in food testing

Therapeutics• focus on the development of therapeutic proteins according a synergistic partnership concept• anti-L-selectin (partner PDL) for polytrauma clinical phase I completed• research and development activities in the field of intensive care, skin disorders, wound healing

and hard tissue repair

Use the synergistic potential of diagnostics and therapeuticsto create integrated health care concepts for niche indications

scil

Scil Group: Management TeamS. Engelhorn, Ph.D., M.D.

G. Schumacher, Ph.D.

J. Bornemann

C. Dony, Ph.D.

J. Feuerstein, Ph.D.

R. Schenk, Ph.D.

U. Martin, M.D.

CEO of Scil Finance Holding. President of Scil Technology Holding. Member and chairman of several trusts

CEO of Scil Technology Holding. 20 years of industrial experience in diagnostics and therapeutics. Former head of R&D at BM/Roche

Vice President, DFO of Scil Technology Holding. Former at KPMG, tax consultant and commercial director at Gebr. März AG and Leonard Moll AG.

Vice President, Research and Development of Scil Technology Holding.Former head of musculoskeletal disorders at BM/Roche, scientist atGenentech Inc.

CEO of Scil Diagnostics. Former global strategic project planning at BM/Roche. Focus: marketing, PSO organization management, partnership management

CEO of Scil Diagnostics. Former head of system development and leaderproject lab diagnostics at BM/Roche. Focus: system and technology concepts and implementation

CEO of Scil Pharmaceuticals. Former head of pharmacology and cardiovascular research at BM/Roche and senior scientist at Hoechst

scil

Scil Pharmaceuticals: Mission

Scil Pharmaceuticals

is a young privately owned company with the mission to use

professional industrial drug-developmentknow how

to develop, manufacture and market innovativebio-pharmaceuticals

scil

Scil Pharmaceuticals: Corporate Profile

Founded in May 1999

Privately owned company

Subsidiary of Scil Technology Holding GmbH

Employees: 17 people, 50 people mid of 2000

Focus:- development of innovative protein pharmaceuticals- focus on niche indications- protein technology services

scil

Scil Pharmaceuticals: Facilities

Munich: Development of protein pharmaceuticals

• Headquarter BioNet (Scil?) Pharma R&D

• International development of protein pharmaceuticals until approval

• 700 square foot lab space, Gründerzentrum Martinsried

• 9000 square foot lab- and office-space (6/2000)

Halle/Leipzig: Protein Technology Services

• Founded by Prof. R. Rudolph, Institute for Biotechnology, Halle• Small scale production of recombinant proteins (up to 10 g)

- samples for pre-clinical research- samples for protein structure analysis/rationale drug design

• 1000 square foot lab space associated with the Institute for Biotechnology• Option for 4200 square foot lab- and office-space (3/2000)

scil

Scil Pharmaceuticals: Core Management TeamCEO

U. Martin

former head of pharmacology and cardiovascular research at BM/Roche; senior scientist at Hoechst

Pre-clinicalResearchC. Dony

Biotechnology

U. Kohnert

PharmaceuticalSciences

N.N.

Non-clinicalDevelopment

U. Martin

ClinicalDevelopment

M. Beckert

Former head ofmusculoskeletaldisorders researchat BM/Roche;scientist at Genentech

Experienced project leaderbiotechnology for reteplase, specialist inpreformulationat BM/Roche

Experienced project leaderpre-clinical/clinical pharma-cology for rete-plase, therap.antibodies, gene therapy

Former head ofclinical researchat MSD

Team of legal (B. Jurisch), patent (B. Huber) and diagnostics (A. Wahlefeld) advisors

scil

Scil Pharmaceuticals: Core Competence

Development of protein pharmaceuticals

from active compound

to approval

scil

Scil Pharmaceuticals: Core CompetenceDevelopment of protein pharmaceuticals

Protein bulk drug

Finished product

Integrated technology platform for bulk drug and finished product- protein process development- formulation/drug delivery- pharmaceutical analyses

Pre-clinic bioanalytics

Clinical development

Regulatory affairs

Experienced steering of non-clinical and clinicaldevelopment activities including GMP manufacturingvia CROs

Team of project leaders with experience in inter-national project development and regulatory filing (FDA & EMEA for RapiLysin®/RetavaseTM)

Approval

scil

Scil Pharmaceuticals: Fast track development of Anti-L-Selectin (BNP 001) in 1999Anti-L-selectin for the treatment of multi organ failure (partner: PDL) after polytrauma

January 15

February 24

March 31

June 2

June 4

July 14

July 28

September

LETTER OF INTENT: PDL - BioNet for anti-L-selectin

Start TECHNICAL TRANSFER (know how, reports and materials)

CONTRACT PDL - BioNet signed

CLINICAL DRUG SUPPLIES released

PHASE I: first in man

DOSE SELECTION FOR PHASE II

Submission of phase II study protocol to CENTRAL ETHICS COMMITTEE of PI

PHASE II (Polytrauma): “first patient in”

scil

Scil Pharmaceuticals: Strategic Focus

• Antibody/protease technologies

Inflammation / immundisorders

Oncology

Cardiovascular

• Tissue regeneration technologies, growth factors

Skin disorders / wound healing

Dental disorders / orthopaedics

scil

Scil Pharmaceuticals: Research & DevelopmentPipeline

Antibody/protease technologies

• Anti-L-selectin multi organ failure, polytrauma- clinical phase II, 10/99- market entry 2002

• -Kristallin technology (research stage collaboration Prof. R. Rudolph)

Tissue regeneration technologies

• Anti-neurodermitis treatment (collaboration Prof. R. Rudolph)- clinical phase I

• Growth factor delivery system, dental application (pre-clinical)

scil

Scil Proteins Halle: Mission

• Founded by Prof. R. Rudolph, Institute for Biotechnology, Halle

• Technology Services,• Small scale production of recombinant proteins

samples for pre-clinical research samples for protein structure analysis, rationale drug design

• 1000 square foot lab space associated with the Institute forBiotechnology

• Option for 4200 square foot lab- and office-space (3/2000)

scil

Scil Proteins Halle: Core Competence

• Customized folding

• Expression systems (pro- and eukaryotic organisms)

• Fermentation facilities: 10 l-, 50 l-, 100 l-reactors (E. coli)

• Highly specialized protein refolding technology - automaticprotein folding reactor for proteins expressed in inclusionbodies (E. coli)

• Proteinpurification: conventional methods and affinity techniquesto guarantee straight forward purification of protein samples

• Physicochemical characterized and proteinprofiling, massspectroscopy, CD, fluorescence/biacore, protein sequencing,etc.

scil

Scil Proteins:Projects of the Institute of Protein Technologies: Prof. R. Rudolph, HalleSuccessful refolding of inclusion body proteins expressed in E. coli

Protein

GLP1-Receptorpro NGFpro BMP2PTH-ReceptorProteinase KEnterokinasePepsinogenProcollagen C Proteinaseh Phosphodiesterase PDE 4HIV ProteaseAntibody fragmentsCD 4Helicase

Partnership

Boehringer MannheimBoehringer MannheimRocheRocheRocheGenetics InstituteSchweizer Rotes Kreuz / NovartisPfizerUniversity Leipzig / AWDUniversity Halle---